The Drug Enforcement Administration (DEA) is currently moving to block a request for expert testimony from an agency official regarding the potential harms of cannabis. This development concerns the upcoming administrative hearing focused on the proposal to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act. The organization Smart Approaches to Marijuana (SAM), a prominent opponent of federal cannabis reform, sought to call Luli Akinfiresoye, a DEA official associated with reports emphasizing the risks associated with cannabis use, to testify during the scheduled proceedings.
The DEA’s resistance to this request suggests a strategic effort to maintain the procedural scope of the hearing, which is set to commence next week. As the industry closely monitors the administrative rescheduling process, this legal maneuvering highlights the tension between established federal perspectives on drug safety and the ongoing regulatory review. The hearing is expected to serve as a critical venue for both proponents and opponents of rescheduling to present their respective evidence.
For stakeholders in the cannabis sector, this procedural conflict represents another layer of complexity in the federal government’s assessment of marijuana’s status. The outcome of these hearings will provide necessary insight into the DEA’s internal deliberations and could influence the speed and implementation of any potential rescheduling efforts. Industry participants remain focused on how these administrative hurdles might affect the timeline for federal policy shifts, which hold significant implications for taxation, research, and operational compliance across the supply chain.
As legal and administrative experts prepare for the start of the hearing, the industry is bracing for a robust debate that will test the evidentiary requirements for federal reclassification.